Fig. 4From: Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastomaSurvival analyses depending on treatment in histological subgroups for the MGMT-promoter unmethylated and methylated tumor cohort. a-b Kaplan-Meier survival curves for patients treated with nimotuzumab (nimo) or placebo (cont) in dichotomized histological subgroups (median split, above median: high, below and equal to median low) for necrosis, P-PRAS40 and P-RPS6 in the MGMT-promoter unmethylated (a) and methylated (b) tumor cohort. P values were calculated using the Wilcoxon testBack to article page